Compass Pathways PLC Sponsored ADR $CMPS Shares Bought by Eagle Health Investments LP

Eagle Health Investments LP boosted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 62.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,519,388 shares of the company’s stock after buying an additional 583,938 shares during the quarter. Compass Pathways accounts for 2.3% of Eagle Health Investments LP’s investment portfolio, making the stock its 15th largest position. Eagle Health Investments LP owned approximately 1.58% of Compass Pathways worth $10,484,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CMPS. Jefferies Financial Group Inc. acquired a new stake in Compass Pathways during the 3rd quarter worth approximately $7,890,000. Nantahala Capital Management LLC lifted its holdings in Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Compass Pathways during the 3rd quarter worth approximately $6,926,000. Two Sigma Investments LP lifted its holdings in Compass Pathways by 838.4% during the 3rd quarter. Two Sigma Investments LP now owns 1,075,277 shares of the company’s stock worth $6,161,000 after buying an additional 960,685 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Compass Pathways by 39.9% in the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after purchasing an additional 774,090 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Compass Pathways News Summary

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $70 price target on Compass Pathways, while raising multiple earnings estimates across 2026 and 2027. The broker’s higher forecasts suggest improving longer-term fundamentals and may be helping support the stock. Compass Pathways analyst estimate updates
• Positive Sentiment: Recent articles also point to retail trader optimism that a major FDA-related catalyst could be brewing, adding momentum to the shares and fueling breakout-style buying interest. CMPS stock is breaking out again — retail traders think a major FDA catalyst is brewing
• Neutral Sentiment: HC Wainwright’s revisions were mixed in direction across periods, but the overall message remained constructive: near-term losses are still expected, yet the firm sees a path to improving earnings over time.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $10.87 on Thursday. The company’s fifty day moving average price is $7.45 and its 200 day moving average price is $6.83. Compass Pathways PLC Sponsored ADR has a 12 month low of $2.25 and a 12 month high of $11.65. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The firm has a market capitalization of $1.47 billion, a P/E ratio of -3.45 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. As a group, sell-side analysts predict that Compass Pathways PLC Sponsored ADR will post -0.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Maxim Group raised their price objective on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a report on Friday, May 15th. B. Riley Financial assumed coverage on shares of Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 price objective on the stock. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Compass Pathways in a report on Tuesday, April 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Compass Pathways has an average rating of “Moderate Buy” and an average price target of $20.58.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.